Synopsis
Synopsis
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(isopropoxycarbonyloxy)ethyl-7-(2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetamido)-3-methoxymethyl-8-oxo-5-thia-1-azabicyclo(4,2,0)-oct-2-ene-2-carboxylate
2. Cephalosporin 807
3. Cs 807
4. Cs-807
5. Doxef
6. U 76252
7. U-76,252
8. Vantin
1. Vantin
2. Banan
3. 87239-81-4
4. Orelox
5. Doxef
6. Cs-807
7. Simplicef
8. Otreon
9. U-76252
10. Podomexef
11. Chebi:3505
12. 2tb00a1z7n
13. Cefodox
14. Nsc-759161
15. (rs)-1-((isopropoxycarbonyl)oxy)ethyl (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)-2-((z)-methoxyimino)acetamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
16. Dsstox_cid_2766
17. Dsstox_rid_76722
18. Cefpodoxime 1-(isopropyloxycarbonyloxy)ethyl Ester
19. Dsstox_gsid_22766
20. Xtum-o
21. 1-{[(propan-2-yloxy)carbonyl]oxy}ethyl (6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
22. 1-{[(propan-2-yloxy)carbonyl]oxy}ethyl 7beta-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-(methoxymethyl)-3,4-didehydrocepham-4-carboxylate
23. Cas-87239-81-4
24. Simplicef [veterinary]
25. Unii-2tb00a1z7n
26. Orelox Paed
27. Ncgc00164598-01
28. Ncgc00183131-01
29. Mfcd00865088
30. Vantin (tn)
31. Cefpodoxime Proxetil [usan:usp:jan]
32. Schembl27071
33. Mls001401428
34. Chembl1201016
35. Dtxsid1022766
36. Cefpodoxime (as Proxetil)
37. Cefpodoxime Proxetil (jp17/usp)
38. Cefpodoxime Proxetil [jan]
39. Hms3715j22
40. Cefpodoxime Proxetil [usan]
41. Cefpodoxime Proxetil, Vantin
42. Hy-n7101
43. Cefpodoxime Proxetil [vandf]
44. Tox21_113377
45. Tox21_113428
46. Bdbm50248233
47. Cefpodoxime Proxetil [mart.]
48. S5350
49. Cefpodoxime Proxetil [usp-rs]
50. Cefpodoxime Proxetil [who-dd]
51. Akos015994692
52. Ccg-221250
53. Ks-1149
54. Nsc 759161
55. Cefpodoxime Proxetil [green Book]
56. (+-)-1-hydroxyethyl (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(z)-(o-methyloxime), Isopropyl Carbonate (ester)
57. Cefpodoxime Proxetil [orange Book]
58. Ru-51807
59. Smr000469193
60. Cefpodoxime Proxetil [ep Monograph]
61. Cefpodoxime Proxetil [usp Impurity]
62. Cefpodoxime Proxetil [usp Monograph]
63. Cefpodoxime Proxetil For Peak Identification
64. Cs-0027614
65. C08115
66. D00920
67. Ab01209734-01
68. 239c814
69. A842048
70. Cefpodoxime Proxetil For Impurity H Identification
71. Cefpodoxime 1-(isopropoxycarbonyloxy)ethyl Ester
72. Cefpodoxime 1-(isopropoxycarbonyloxy)ethyl Ester [mi]
73. (+/-)-1-hydroxyethyl (+)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7 (sup 2)-(z)-(o-methyloxime), Isopropyl Carbonate (ester)
74. (6r,7r)-1-((isopropoxycarbonyl)oxy)ethyl 7-((z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
75. (6r,7r)-7-(((2z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid 1-(((1-methylethoxy)carbonyl)oxy)ethyl Ester
76. 1-({[(1-methylethyl)oxy]carbonyl}oxy)ethyl (6r,7r)-7-({(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
77. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, 1-(((1-methylethoxy)carbonyl)oxy)ethyl Ester, (6r-(6.alpha.,7.beta.(z)))-
78. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, 1-(((1-methylethoxy)carbonyl)oxy)ethyl Ester, (6r-(6alpha,7beta(z)))-
79. 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid, 7-[[(2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-, 1-[[(1-methylethoxy)carbonyl]oxy]ethyl Ester, (6r,7r)-
| Molecular Weight | 557.6 g/mol |
|---|---|
| Molecular Formula | C21H27N5O9S2 |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 13 |
| Exact Mass | 557.12501980 g/mol |
| Monoisotopic Mass | 557.12501980 g/mol |
| Topological Polar Surface Area | 235 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 976 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Cefpodoxime proxetil |
| PubMed Health | Cefpodoxime Proxetil (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. The chemical name is (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3-m... |
| Active Ingredient | Cefpodoxime proxetil |
| Dosage Form | Tablet; For suspension |
| Route | Oral |
| Strength | eq 100mg base; eq 200mg base; eq 100mg base/5ml; eq 50mg base/5ml |
| Market Status | Prescription |
| Company | Ranbaxy; Aurobindo Pharma; Sandoz; Orchid Hlthcare |
| 2 of 2 | |
|---|---|
| Drug Name | Cefpodoxime proxetil |
| PubMed Health | Cefpodoxime Proxetil (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. The chemical name is (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R,7R)-7-[2-(2-amino-4-thiazolyl)-2-{(Z)methoxyimino}acetamido]-3-m... |
| Active Ingredient | Cefpodoxime proxetil |
| Dosage Form | Tablet; For suspension |
| Route | Oral |
| Strength | eq 100mg base; eq 200mg base; eq 100mg base/5ml; eq 50mg base/5ml |
| Market Status | Prescription |
| Company | Ranbaxy; Aurobindo Pharma; Sandoz; Orchid Hlthcare |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-03-09
Pay. Date : 2020-01-21
DMF Number : 34502
Submission : 2020-02-17
Status : Active
Type : II
Certificate Number : CEP 2020-399 - Rev 02
Issue Date : 2025-11-19
Type : Chemical
Substance Number : 2341
Status : Valid
Registration Number : 303MF10058
Registrant's Address : No. 849 Dongjia Town, Licheng District, Jinan, Shandong, China
Initial Date of Registration : 2021-04-02
Latest Date of Registration :
NDC Package Code : 51810-052
Start Marketing Date : 2022-06-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Seongyi Bio Co., Ltd.
Registration Date : 2022-07-01
Registration Number : 20200618-25-A-359-12(1)
Manufacturer Name : Qilu Antibiotics Pharmaceutical Co., Ltd.
Manufacturer Address : No.849 Dongjia Town, Licheng District, Jinan, Shandong Province, China

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20076
Submission : 2006-12-26
Status : Active
Type : II
Certificate Number : R0-CEP 2013-064 - Rev 00
Issue Date : 2013-09-30
Type : Chemical
Substance Number : 2341
Status : Withdrawn by Holder
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2014-06-11
Registration Number : 20140611-25-A-300-07
Manufacturer Name : Sandoz GmbH
Manufacturer Address : Biochemiestraβe 10, 6250 Kundl, Austria

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23572
Submission : 2010-02-23
Status : Active
Type : II
Date of Issue : 2022-05-17
Valid Till : 2025-05-16
Written Confirmation Number : WC-00008A1
Address of the Firm :

GDUFA
DMF Review : Reviewed
Rev. Date : 2017-02-27
Pay. Date : 2016-12-27
DMF Number : 29791
Submission : 2015-09-14
Status : Active
Type : II
Date of Issue : 2025-11-07
Valid Till : 2025-09-30
Written Confirmation Number : WC-0190
Address of the Firm :
NDC Package Code : 61788-5000
Start Marketing Date : 2004-05-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Youngjin Pharmaceutical Co., Ltd.
Registration Date : 2017-08-03
Registration Number : 20150410-25-A-305-10(1)
Manufacturer Name : Covalent Laboratories Pvt. Ltd
Manufacturer Address : Sy. No.374, Gundla Machanoor Village, Hathnoor Mandal, Sangareddy District - 502 296, Telangana State,

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18505
Submission : 2005-07-11
Status : Active
Type : II
Registration Number : 306MF10078
Registrant's Address : Plot No. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu District-603 110, Tamilnadu, INDIA.
Initial Date of Registration : 2024-06-12
Latest Date of Registration :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16542
Submission : 2003-04-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2010-283 - Rev 01
Issue Date : 2017-12-05
Type : Chemical
Substance Number : 2341
Status : Valid
Registration Number : 225MF10129
Registrant's Address : Biochemiesstrasse 10, 6250 Kundl, Austria
Initial Date of Registration : 2013-07-09
Latest Date of Registration :
Registrant Name : HK Innoen Co., Ltd.
Registration Date : 2014-07-25
Registration Number : 20140611-25-A-300-07(1)
Manufacturer Name : Sandoz GmbH
Manufacturer Address : Biochemiestraβe 10, 6250 Kundl, Austria

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6937
Submission : 1987-04-15
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9886
Submission : 1987-04-15
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
16
PharmaCompass offers a list of Cefpodoxime Proxetil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cefpodoxime Proxetil manufacturer or Cefpodoxime Proxetil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefpodoxime Proxetil manufacturer or Cefpodoxime Proxetil supplier.
A Cefpodoxime manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefpodoxime, including repackagers and relabelers. The FDA regulates Cefpodoxime manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefpodoxime API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefpodoxime manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Cefpodoxime supplier is an individual or a company that provides Cefpodoxime active pharmaceutical ingredient (API) or Cefpodoxime finished formulations upon request. The Cefpodoxime suppliers may include Cefpodoxime API manufacturers, exporters, distributors and traders.
click here to find a list of Cefpodoxime suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Cefpodoxime DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefpodoxime active pharmaceutical ingredient (API) in detail. Different forms of Cefpodoxime DMFs exist exist since differing nations have different regulations, such as Cefpodoxime USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefpodoxime DMF submitted to regulatory agencies in the US is known as a USDMF. Cefpodoxime USDMF includes data on Cefpodoxime's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefpodoxime USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefpodoxime suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cefpodoxime Drug Master File in Japan (Cefpodoxime JDMF) empowers Cefpodoxime API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cefpodoxime JDMF during the approval evaluation for pharmaceutical products. At the time of Cefpodoxime JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cefpodoxime suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefpodoxime Drug Master File in Korea (Cefpodoxime KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefpodoxime. The MFDS reviews the Cefpodoxime KDMF as part of the drug registration process and uses the information provided in the Cefpodoxime KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefpodoxime KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefpodoxime API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefpodoxime suppliers with KDMF on PharmaCompass.
A Cefpodoxime CEP of the European Pharmacopoeia monograph is often referred to as a Cefpodoxime Certificate of Suitability (COS). The purpose of a Cefpodoxime CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefpodoxime EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefpodoxime to their clients by showing that a Cefpodoxime CEP has been issued for it. The manufacturer submits a Cefpodoxime CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefpodoxime CEP holder for the record. Additionally, the data presented in the Cefpodoxime CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefpodoxime DMF.
A Cefpodoxime CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefpodoxime CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefpodoxime suppliers with CEP (COS) on PharmaCompass.
A Cefpodoxime written confirmation (Cefpodoxime WC) is an official document issued by a regulatory agency to a Cefpodoxime manufacturer, verifying that the manufacturing facility of a Cefpodoxime active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefpodoxime APIs or Cefpodoxime finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefpodoxime WC (written confirmation) as part of the regulatory process.
click here to find a list of Cefpodoxime suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefpodoxime as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cefpodoxime API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cefpodoxime as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cefpodoxime and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefpodoxime NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cefpodoxime suppliers with NDC on PharmaCompass.
Cefpodoxime Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefpodoxime GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cefpodoxime GMP manufacturer or Cefpodoxime GMP API supplier for your needs.
A Cefpodoxime CoA (Certificate of Analysis) is a formal document that attests to Cefpodoxime's compliance with Cefpodoxime specifications and serves as a tool for batch-level quality control.
Cefpodoxime CoA mostly includes findings from lab analyses of a specific batch. For each Cefpodoxime CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefpodoxime may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefpodoxime EP), Cefpodoxime JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefpodoxime USP).